Oxytocin as a potential defence against Covid- 19?
Identifieur interne : 000498 ( Pmc/Corpus ); précédent : 000497; suivant : 000499Oxytocin as a potential defence against Covid- 19?
Auteurs : Amélie Soumier ; Angela SiriguSource :
- Medical Hypotheses [ 0306-9877 ] ; 2020.
Url:
DOI: 10.1016/j.mehy.2020.109785
PubMed: 32344303
PubMed Central: 7177061
Links to Exploration step
PMC:7177061Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oxytocin as a potential defence against Covid- 19?</title><author><name sortKey="Soumier, Amelie" sort="Soumier, Amelie" uniqKey="Soumier A" first="Amélie" last="Soumier">Amélie Soumier</name></author><author><name sortKey="Sirigu, Angela" sort="Sirigu, Angela" uniqKey="Sirigu A" first="Angela" last="Sirigu">Angela Sirigu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32344303</idno><idno type="pmc">7177061</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177061</idno><idno type="RBID">PMC:7177061</idno><idno type="doi">10.1016/j.mehy.2020.109785</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000498</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000498</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Oxytocin as a potential defence against Covid- 19?</title><author><name sortKey="Soumier, Amelie" sort="Soumier, Amelie" uniqKey="Soumier A" first="Amélie" last="Soumier">Amélie Soumier</name></author><author><name sortKey="Sirigu, Angela" sort="Sirigu, Angela" uniqKey="Sirigu A" first="Angela" last="Sirigu">Angela Sirigu</name></author></analytic><series><title level="j">Medical Hypotheses</title><idno type="ISSN">0306-9877</idno><idno type="eISSN">1532-2777</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Wang, P" uniqKey="Wang P">P. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thibonnier, M" uniqKey="Thibonnier M">M. Thibonnier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="An, X" uniqKey="An X">X. An</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y. Liu</name></author><author><name sortKey="Conboy, I" uniqKey="Conboy I">I. Conboy</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="letter"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Med Hypotheses</journal-id><journal-id journal-id-type="iso-abbrev">Med. Hypotheses</journal-id><journal-title-group><journal-title>Medical Hypotheses</journal-title></journal-title-group><issn pub-type="ppub">0306-9877</issn><issn pub-type="epub">1532-2777</issn><publisher><publisher-name>Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32344303</article-id><article-id pub-id-type="pmc">7177061</article-id><article-id pub-id-type="publisher-id">S0306-9877(20)30680-0</article-id><article-id pub-id-type="doi">10.1016/j.mehy.2020.109785</article-id><article-id pub-id-type="publisher-id">109785</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Oxytocin as a potential defence against Covid- 19?</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Soumier</surname><given-names>Amélie</given-names></name></contrib><contrib contrib-type="author" id="au010"><name><surname>Sirigu</surname><given-names>Angela</given-names></name><email>sirigu@isc.cnrs.fr</email><xref rid="cor1" ref-type="corresp">⁎</xref></contrib><aff id="af005">Institute of Cognitive Science Marc Jeannerod, UMR 5229, CNRS, University Claude Bernard LyonI, Bron, France</aff></contrib-group><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author. <email>sirigu@isc.cnrs.fr</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>23</day><month>4</month><year>2020</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="epub"><day>23</day><month>4</month><year>2020</year></pub-date><elocation-id>109785</elocation-id><history><date date-type="received"><day>5</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>© 2020 Published by Elsevier Ltd.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder></copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p id="p0005">To the editor,</p><p id="p0010">According to the research advances on COVID-19, we proposed that oxytocin (OT) a nonapeptide hormone acting in the body and the brain, constitutes a biological target against coronavirus infection, especially in high-risk population, with underlying conditions including diabetes, high blood pressure, cardiovascular issues and obesity.</p><p id="p0015">OT exerts a dual effect by mobilizing the immune defense potential, and by suppressing pathogenic responses due to over-reactions of the innate immunity. In human, increase in plasma OT levels reported in the early phases of infectious disease, can limit the excessive pro-inflammatory and oxidative stress reactions, by decreasing interleukins levels in the macrophages <xref rid="b0005" ref-type="bibr">[1]</xref>. OT exerts metabolic function role in cardiovascular disease (by regulating, heart rate, blood pressure, muscle contraction), in diabetes (via glucose uptake and insulin secretion), and obesity (food intake and satiety), in gastric injury (by antiulcer properties), and in osteoporosis (with bone formation and resorption). These effects can be explained by the presence of local OT producing cells (brain, heart, gastrointestinal tract), and by extensive expression of OT receptors.</p><p id="p0020">Of particular interest to Covid-19, is the nitric oxide (NO), which is a key signalling molecule acting as a host response modulator in viral infections. In humans, activation of the OT receptor, which are expressed by endothelial cells in the pulmonary artery, produce a vasolidatory effect via stimulation of the nitric oxide (NO) pathway <xref rid="b0010" ref-type="bibr">[2]</xref>. In animal models of acute lung injury, OT exposure reduces the expression of inflammatory proteins in the lung tissue <xref rid="b0015" ref-type="bibr">[3]</xref>. Literature also reveals that viral infections in human (including influenza) attenuate OT receptor expression, indicating a key role for the OT system for human health <xref rid="b0020" ref-type="bibr">[4]</xref>. As OT secretion and levels seems to adjust to pathogen threat and infection, to elicit initial adaptive inhibitory responses and to restore the host homeostasis, OT administration, which is safely deliverable in humans (by nasal spray or intravenous injection) could be used as a prospective therapeutic agent for Covid-19 viral replication and infection.</p><sec id="s0005"><title>Funding sources</title><p id="p0025">None</p></sec><sec id="s0010"><title>Prior presentation</title><p id="p0030">No data from this manuscript were presented in a previous scientific meeting.</p></sec><sec id="s0015"><title>Declaration of Competing Interest</title><p id="p0035">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.</given-names></name></person-group><article-title>Oxytocin-secreting system: a major part of the neuroendocrine center regulating immunologic activity</article-title><source>J Neuroimmunol.</source><volume>289</volume><year>2015</year><fpage>152</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">26616885</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Thibonnier</surname><given-names>M.</given-names></name></person-group><article-title>Human Vascular Endothelial Cells Express Oxytocin Receptors</article-title><source>Endocrinology.</source><volume>140</volume><issue>3</issue><year>1999</year><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">10067857</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>An</surname><given-names>X.</given-names></name></person-group><article-title>Protective effect of oxytocin on LPS-induced acute lung injury in mice</article-title><source>Sci Rep.</source><volume>9</volume><year>2019</year><fpage>2836</fpage><pub-id pub-id-type="pmid">30808956</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Conboy</surname><given-names>I.</given-names></name></person-group><article-title>Unexpected evolutionarily conserved rapid effects of viral infection on oxytocin receptor and TGF-β/pSmad3</article-title><source>Skeletal Muscle</source><volume>7</volume><year>2017</year><fpage>7</fpage><pub-id pub-id-type="pmid">28506310</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000498 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000498 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7177061
|texte= Oxytocin as a potential defence against Covid- 19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:32344303" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |